BFM
PYXS icon

Boothbay Fund Management’s Pyxis Oncology PYXS Stock Holding History

Boothbay Fund Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-99,100
Closed -$364K – 1837
2024
Q3 		$364K Hold
99,100
– – 0.01% 1128
2024
Q2 		$328K Buy
+99,100
New +$417K 0.01% 1132

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Boothbay Fund Management's PYXS Position: Q2 2025 in Review

Boothbay Fund Management sold out of Pyxis Oncology (PYXS) in Q2 2025, closing a stake of 181,042 shares — an estimated $177K sold.

Boothbay Fund Management first reported a position in PYXS in Q1 2024 and held it in 5 quarters. The position peaked at $2.1M in Q1 2024. 74 funds tracked by Wall St. Rank hold PYXS as of Q2 2025.

  • Boothbay Fund Management reported no remaining Pyxis Oncology position as of Q2 2025 after selling out during the quarter.
  • Boothbay Fund Management sold 181,042 Pyxis Oncology shares in Q2 2025, an estimated $177K.
  • Boothbay Fund Management first reported a position in Pyxis Oncology in Q1 2024 and held it in 5 quarters.
  • Boothbay Fund Management's Pyxis Oncology position peaked at $2.1M in Q1 2024.
  • 74 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2025.

Based on Boothbay Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.